In the last three months, 4 analysts have published ratings on Caribou Biosciences CRBU, offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $15.25, a high estimate of $24.00, and a low estimate of $9.00. This current average represents a 19.74% decrease from the previous average price target of $19.00.
Interpreting Analyst Ratings: A Closer Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Caribou Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Robert Burns | HC Wainwright & Co. | Maintains | Buy | $9.00 | $9.00 |
| Robert Burns | HC Wainwright & Co. | Lowers | Buy | $9.00 | $24.00 |
| Asthika Goonewardene | Truist Securities | Maintains | Buy | $19.00 | $19.00 |
| Robert Burns | HC Wainwright & Co. | Maintains | Buy | $24.00 | $24.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Caribou Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Caribou Biosciences compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Caribou Biosciences's stock. This analysis reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Caribou Biosciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Caribou Biosciences analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Caribou Biosciences: A Closer Look
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Financial Insights: Caribou Biosciences
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Caribou Biosciences's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -30.64% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Caribou Biosciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -1697.57%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Caribou Biosciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -11.59%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Caribou Biosciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -9.83%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Caribou Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.08.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
